Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680628 · ClinicalTrials.gov registry record · Phase 3
Clot Dissolving Treatment for Blood Clots in the Lungs
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT00680628 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 83 participants.
The verdict
NCT00680628, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.
Interventions
- DRUG Tenecteplase + Enoxaparin
- DRUG 0.9% Saline + Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680628
The ClinicalTrials.gov registry entry for NCT00680628 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenecteplase + Enoxaparin is the first listed.
NCT00680628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00680628 about?
NCT00680628 is a clinical study titled "Clot Dissolving Treatment for Blood Clots in the Lungs". The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.
What is the current status of trial NCT00680628?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2008-05. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00680628?
The interventions under investigation include: Tenecteplase + Enoxaparin (DRUG), 0.9% Saline + Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00680628?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.